| Literature DB >> 32605255 |
Aleksandra Zielińska1,2, Beatriz Costa1, Maria V Ferreira1, Diogo Miguéis1, Jéssica M S Louros1, Alessandra Durazzo3, Massimo Lucarini3, Piotr Eder4, Marco V Chaud5, Margreet Morsink6,7,8, Niels Willemen6,8, Patrícia Severino6,9,10, Antonello Santini11, Eliana B Souto1,12.
Abstract
This review offers a systematic discussion about nanotoxicology and nanosafety associated with nanomaterials during manufacture and further biomedical applications. A detailed introduction on nanomaterials and their most frequently uses, followed by the critical risk aspects related to regulatory uses and commercialization, is provided. Moreover, the impact of nanotoxicology in research over the last decades is discussed, together with the currently available toxicological methods in cell cultures (in vitro) and in living organisms (in vivo). A special focus is given to inorganic nanoparticles such as titanium dioxide nanoparticles (TiO2NPs) and silver nanoparticles (AgNPs). In vitro and in vivo case studies for the selected nanoparticles are discussed. The final part of this work describes the significance of nano-security for both risk assessment and environmental nanosafety. "Safety-by-Design" is defined as a starting point consisting on the implementation of the principles of drug discovery and development. The concept "Safety-by-Design" appears to be a way to "ensure safety", but the superficiality and the lack of articulation with which it is treated still raises many doubts. Although the approach of "Safety-by-Design" to the principles of drug development has helped in the assessment of the toxicity of nanomaterials, a combination of scientific efforts is constantly urgent to ensure the consistency of methods and processes. This will ensure that the quality of nanomaterials is controlled and their safe development is promoted. Safety issues are considered strategies for discovering novel toxicological-related mechanisms still needed to be promoted.Entities:
Keywords: Safety-by-Design; biological systems; human health; nanomaterials; nanoparticles; nanosafety; nanotoxicology; risk assessment; toxicity tests
Mesh:
Substances:
Year: 2020 PMID: 32605255 PMCID: PMC7369733 DOI: 10.3390/ijerph17134657
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1The impact of nanomaterial life cycle on the environment.
Figure 2The risk assessment methodology for nanomaterials (NMs) based on Registration, Evaluation, Authorization and restriction of Chemical Substances (REACH) requirements.
Figure 3Relevant properties of nanomaterials in view of their safety assessment and the influence over a product’s lifecycle.
Figure 4Schematic of the Safety-by-Design principle.
The advantages and drawbacks of the various in vitro methods.
| Type | Advantages | Drawbacks | References |
|---|---|---|---|
| 2D cell culture | |||
| Upright NM exposure | Easy experiment set-up; | Agglomeration of nanoparticles; | [ |
| Surface-based NM presentation | Exact NM/µm; | NM–substrate interactions influence internalization and toxicity results; | [ |
| Inverted cell culture | Assessment of buoyant NM nanotoxicity | Limited use for larger-sized or insoluble NMs | [ |
| Air liquid interface | More physiologically relevant; | Limited to airborne NMs; | [ |
| 3D cell culture | |||
| Co-culture | Promotes in vivo-like cell–cell interactions; | Still lacks 3D microenvironment | [ |
| Spheroids and organoids | More in vivo-like complexity; | Heterogeneity; | [ |
| Organ-on-Chip | High throughput; | Surface effects stemming from small dimensions; | [ |
| Precision-cut tissue slices | Compatible with a range of tissue samples and animal species; | Tissue damage due to slicing; | [ |
The advantages and drawbacks of the various in vivo methods. ADME: Absorption, distribution, metabolism, and excretion.
| Type | Advantages | Drawbacks | Source(s) |
|---|---|---|---|
| Aquatic models | |||
| Planktonic crustaceans | Standardized protocols and guidelines; | Primarily used as pre-screening method; | [ |
| Zebrafish | High throughput; | Difficult monitoring of rapid developmental process; | [ |
| Mammal models | |||
| Small rodents | Multiple routes of exposure; | Ethical concerns; | [ |